MGTX earnings analysis
What we found in MGTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
MeiraGTx reported $321.434 million of revenue and $1.71 diluted EPS, compared with $3.691 million of revenue and a $0.48 diluted loss in the prior-year quarter. The increase was driven by $204.643 million of license revenue and $104.906 million of related-party service revenue, but the filing characterizes profitability as primarily non-recurring. Liquidity improved to $145.4 million of cash, cash equivalents and restricted cash, with management estimating funding into the second half of 2028, although the company remains a clinical-stage business with an accumulated deficit of approximately $701.8 million and substantial future financing and development risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Collaboration revenue surged
- Revenue was $321.434 million, up from $3.691 million in the prior-year quarter, an increase of approximately $317.743 million or 86.1x. The result was primarily driven by $204.643 million of license revenue and $104.906 million of related-party service revenue.
- Returned to diluted profitability
- Diluted EPS was $1.71 versus a diluted loss of $0.48 in the prior-year quarter, a $2.19 per-share improvement. The filing indicates profitability was primarily attributable to non-recurring transactions.
- Liquidity runway extended
- Cash, cash equivalents and restricted cash totaled $145.4 million at June 30, 2026. Management estimates available resources and identified proceeds will fund operating expenses and capital expenditures into the second half of 2028.
- Secured additional financing capacity
- The company entered into a Royalty Note Purchase Agreement providing for up to $375 million of purchases, including an initial $100 million purchase on June 30, 2026 and a $25 million second purchase on July 17, 2026.
- Eliminated floating-rate debt
- The company repaid all outstanding borrowings and terminated its prior Notes Purchase Agreement on June 30, 2026, leaving no fluctuating-rate debt outstanding at quarter end.
- Regulatory milestones advancing
- Management expects global regulatory filings for bota-vec in 2026, while the AAV2-hAQP1 program could support a BLA filing in mid-2027. AAV-hAQP1 received Breakthrough Therapy Designation in March 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Non-recurring profit and large deficit
- Current-period profitability is not necessarily sustainable: the filing states that profitability was primarily attributable to non-recurring transactions, while accumulated deficit was approximately $701.8 million as of June 30, 2026.
- Royalty financing encumbers future economics
- The Royalty Note Purchase Agreement permits up to $375 million of senior secured notes and requires Revenue Payments equal to 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1 and bota-vec after approval. The obligations are secured by cash, receivables, property, plant and equipment, equity interests and specified product assets.
- Unhedged foreign-exchange exposure
- Management estimates a 10% unfavorable currency movement would create an additional foreign-currency loss of approximately $14.3 million for the six months ended June 30, 2026. The company held no foreign-currency forward contracts as of June 30, 2026.
- No approved commercial product
- The company has no approved products for commercial sale and states it has not completed any clinical development program required for product approval. Regulatory uncertainty remains material for programs including bota-vec and AAV-hAQP1.
- Clinical development remains cash intensive
- The company expects continued significant expenses and operating losses as it advances clinical programs and manufacturing activities, despite reporting $1.71 of diluted EPS in the current quarter.
- Ongoing equity dilution risk
- The company raised $28.2 million through its at-the-market program during the six months ended June 30, 2026 by issuing 3,164,365 ordinary shares, creating potential dilution if additional equity is needed.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.71
- Segment
- License revenue: $204.643 million
- Segment
- Related-party service revenue: $104.906 million
What they said about what is next.
No formal numeric revenue or EPS guidance was provided. Management estimates that cash, receivables, the $25.0 million second Royalty Note purchase, $10.0 million of third-quarter equity proceeds, and the expected $95.0 million Hologen upfront payment and reimbursements will fund operating and capital needs into the second half of 2028. The estimate excludes $135.0 million of potential near-term Lilly milestone consideration.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- MeiraGTx reported a significant revenue increase of approximately 382% year-over-year, achieving $75 million in Q4 2025, compared to $21 million in Q4 2024. EPS turned positive at $0.19, a remarkable turnaround from a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MGTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever